Referenties
- Cervantes, F., Correa, J. G., Pérez, I., García-Gutiérrez, V., Redondo, S., Colomer, D., Jiménez-Velasco, A., Steegmann, J. L., Sánchez-Guijo, F., Ferrer-Marín, F., Pereira, A., & Osorio, S. (2017). Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response. Annals of Hematology, 96(1), 81–85. https://doi.org/10.1007/s00277-016-2839-z
- Clark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Pocock, C., Smith, G., Byrne, J. L., de Lavallade, H., O’Brien, S. G., Coffey, T., Foroni, L., & Copland, M. (2017). De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. The Lancet Haematology, 4(7), e310–e316. https://doi.org/10.1016/S2352-3026(17)30066-2
- CMyCML: https://www.cmycml.nl/wat-cml
- CML behandelrichtlijn versie 2018: hovon-cml-richtlijn-14-04-2018_geautoriseerd.pdf (hematologienederland.nl)